— Know what they know.
Not Investment Advice

JNCE NASDAQ

Jounce Therapeutics, Inc.
1W: -2.6% 1M: -1.1% 3M: +55.4% 1Y: -64.0% 3Y: -64.8% 5Y: -90.7%
$1.88
Last traded 2023-05-05 — delisted
NASDAQ · Healthcare · Biotechnology · $99.0M mcap · 30M float · 11.63% daily turnover

📊 Key Metrics

TTM
$82M
Revenue
+204.8% YoY
$-51M
Net Income
+16.0% YoY
$-30M
Free Cash Flow
+64.5% YoY
100.0%
Gross Margin
61.4%
Op. Margin
62.1%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

⚠️ Cash Burn Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE-25.0%
ROA-21.9%
ROIC-1149.6%

Valuation

P/E-1.9
P/B0.5
EV/EBITDA2.4

Leverage

Debt/Equity0.05
Current Ratio8.37
Interest Cov.0.0x

Quality Scores

Piotroski F4/9
Altman Z-0.20
Beneish M2718396.30

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms